Vendor Intelligence Report: Haikou Mingheng Technology

Published 3 Jul 2026. 26-page investigative report on who is behind Haikou Mingheng Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 24 Finnrick lab tests, Haikou Mingheng Technology records 19 pass / 4 fail, for an overall pass rate of 79%. The Technology catalog is not a blanket reject: Retatrutide is the strongest tested product and the most defensible choice if a buyer is already committed to this seller. Tirzepatide needs current batch verification, while Ipamorelin is the weakest signal; under stricter fill and quantity grading, the record becomes less forgiving.

The investigation’s sharper issue is provenance. Chinese registry extracts point to a recently registered Hainan micro-entity with low registered capital, a commercial-plaza shop address, and no located public pharmaceutical-manufacturing authorization, while eCHEMI copy claims a 2019 establishment, larger staffing, and GMP or plant language.

The channel map is also crowded. Technology, Biotechnology and no-suffix Mingheng storefronts share brand/address patterns but not clearly interchangeable legal accountability or stock; a Mandy price list, an X seller account, XCHEMI traces and a non-resolving email domain add useful corroboration but no authoritative channel-verification system. Separate Biotechnology quality signals are treated as adjacent-entity caution, not as a rescore of Technology.

Supply-chain and buyer-experience intelligence adds a practical warning. A COA-clustering analysis moves Mingheng into a different sourcing group in 2026, field notes report tested vials without batch identifiers, and a single Reddit allegation describes USDT payment followed by photos/tracking but no moving package. The report is therefore product-specific: potentially usable for selected Technology batches, not a vendor-wide trust shortcut.

Inside the full report:

  • Appendix A Finnrick laboratory data with row-level reconciliation, per-product pass/fail rates, spark grids and methodology-divergence charts for all 3 Technology products
  • Chinese registry extracts contrasting the Technology entity with eCHEMI establishment, staff, plant and GMP claims
  • Marketplace footprint map covering eCHEMI Technology, Biotechnology, the third Mingheng storefront, TradeWheel and XCHEMI
  • Domain and sales-persona trail for xtmingheng.com, Mandy, Ms. Zhao, Anna and the X promotion account
  • GLP-1 Forum COA-clustering analysis and Reddit buyer-experience exhibits, including the USDT non-delivery allegation
  • Buyer verification checklist for legal entity, batch-matched COAs, vial labels and payment controls

Risk assessment

  • Misrepresented manufacturing credentials — high: eCHEMI plant/GMP/2019/staff claims conflict with 2024 QCC registration, 200,000 RMB capital, a shop-unit address and no located public pharma-manufacturing licence.
  • Batch-traceability and COA-matching risk — high: Field notes state tested vials lacked batch identifiers, preventing reliable COA matching, recall targeting or adverse-event tracing.
  • Product-specific quality consistency risk — medium: Tirzepatide is 78.95% (10 tests; 8 pass / 2 fail) and Ipamorelin is 73.7% (5 tests; 4 pass / 1 fail), so current batch-matched retesting is warranted.
  • Brand-confusion and channel-verification risk — medium: Three Mingheng eCHEMI storefronts, Technology/Biotechnology/Pharmaceutical naming, multiple contacts and a non-resolving email domain leave no authoritative channel-verification system.
  • Upstream sourcing-change risk — medium: Broker-style records plus GLP-1 Forum Group 2 drift suggest possible manufacturer/finisher changes, making historic test performance less predictive of current batches.
  • Non-delivery and irreversible-payment risk — medium: A mid-June 2026 Reddit buyer alleged USDT payment followed by unmoved tracking; single-source, but enough to avoid irreversible large orders.